Evidence map›Paper›PMID 37558474›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Hodgkin Lymphoma-related Inflammatory Modification-displayed Castleman Disease-like Histological Features and Positron Emission Tomography/Computed Tomography Usefulness for the Differential Diagnosis.

Hirofumi Yamauchi, Mamiko Momoki, Yutaro Kamiyama, Tadahiro Gunji, Hiroki Yokoyama, Takeshi Saito, David Boutboul, Eric Oksenhendler, Shingo Yano

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Hirofumi YamauchiDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Mamiko MomokiDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Yutaro KamiyamaDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Tadahiro GunjiDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Hiroki YokoyamaDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Takeshi SaitoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
David BoutboulDepartment of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), France.
Eric OksenhendlerDepartment of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), France.
Shingo YanoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Jikei University School of Medicine · JPAssistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hodgkin lymphoma (HL) and idiopathic multicentric Castleman disease (iMCD) are markedly different conditions. However, in some cases, histological similarities caused by elevated cytokines, including interleukin-6, can lead to a misdiagnosis of HL as Castleman disease (CD). We herein report a patient with HL who had been diagnosed with CD by an expert panel and for whom an additional biopsy was useful for determining the correct diagnosis. Furthermore, we analyzed the positron emission tomography/computed tomography findings at the diagnosis and found that the maximum standardized uptake value was useful for distinguishing HL from iMCD.

Indexed as

Castleman DiseaseHodgkin DiseaseDiagnosis, DifferentialFluorodeoxyglucose F18HumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Castleman diseaseHodgkin lymphomainterleukin-6PET/CTSUVmax

Identifiers

PMID37558474
PMCPMC11045375
OpenAlexW4385654052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.